Incyte

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Incyte and other ETFs, options, and stocks.

About INCY

Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. It focuses on hematology and oncology, and inflammation and autoimmunity therapeutic areas. 

CEO
William J. Meury
CEOWilliam J. Meury
Employees
2,844
Employees2,844
Headquarters
Wilmington, Delaware
HeadquartersWilmington, Delaware
Founded
1991
Founded1991
Employees
2,844
Employees2,844

INCY Key Statistics

Market cap
22.92B
Market cap22.92B
Price-Earnings ratio
16.09
Price-Earnings ratio16.09
Dividend yield
Dividend yield
Average volume
2.31M
Average volume2.31M
High today
$115.69
High today$115.69
Low today
$112.89
Low today$112.89
Open price
$115.48
Open price$115.48
Volume
1.53M
Volume1.53M
52 Week high
$115.69
52 Week high$115.69
52 Week low
$66.83
52 Week low$66.83

Stock Snapshot

With a market cap of 22.92B, Incyte(INCY) trades at $115.49. The stock has a price-to-earnings ratio of 16.09.

On 2026-06-30, Incyte(INCY) stock moved within a range of $112.89 to $115.69. With shares now at $115.49, the stock is trading +2.3% above its intraday low and -0.2% below the session's peak.

Trading volume for Incyte(INCY) stock has reached 1.53M, versus its average volume of 2.31M.

Over the past 52 weeks, Incyte(INCY) stock has traded between a high of $115.69 and a low of $66.83.

Over the past 52 weeks, Incyte(INCY) stock has traded between a high of $115.69 and a low of $66.83.

INCY News

MarketWatch 3d
Incyte Corp. stock outperforms competitors on strong trading day - MarketWatch

...

Incyte Corp. stock outperforms competitors on strong trading day - MarketWatch
TipRanks 4d
Incyte Winds Down Itacitinib Rollover Study: What Investors Should Know

Incyte (INCY) announced an update on their ongoing clinical study. Unlock powerful investing tools and data-driven insights with TipRanks Premium for more conf...

TipRanks 4d
Incyte announces positive CHMP opinion of Opzelura Cream

Incyte (INCY) announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has issued a positive opinion recommending the...

Analyst ratings

55%

of 29 ratings
Buy
41.4%
Hold
55.2%
Sell
3.4%

More INCY News

TipRanks 4d
Incyte price target raised to $113 from $103 at UBS

UBS raised the firm’s price target on Incyte (INCY) to $113 from $103 and keeps a Neutral rating on the shares. The firm sees biopharma value stocks such as Inc...

Simply Wall St 4d
Incyte Lands Fresh Clinical Wins, Is It Fully Valued?

Incyte (INCY) stock is drawing fresh attention after a run of clinical and regulatory updates, including pivotal lymphoma data, positive rare disease results, e...

Incyte Lands Fresh Clinical Wins, Is It Fully Valued?
Simply Wall St 7d
What Incyte's Oncology And Rare-Disease Pipeline Milestones Mean For Shareholders

In mid-June 2026, Mirum Pharmaceuticals and Incyte reported pivotal PROGRESS Phase 2 data and an FDA Priority Review for zilurgisertib in ultra-rare fibrodyspla...

What Incyte's Oncology And Rare-Disease Pipeline Milestones Mean For Shareholders

People also own

Based on the portfolios of people who own INCY. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.